Previous studies have found that activation of the MAPK pathway in melanoma by mutation of BRAF8, nuclear accumulation of β-catenin9, PI3K activation10, or CDKN2A deletion11 activate the promoter of BRN2. Here, POU3F2 is linked to melanoma.